Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
$0.11
+3.5%		$0.13
$0.10
▼
$0.60
N/AN/A13,072 shs1,124 shs
iSpecimen Inc. stock logo
ISPC
iSpecimen
$2.24
+0.9%		$2.46
$1.77
▼
$127.20
$3.38M1.66107,006 shs67,517 shs
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.00
$0.01
$0.00
▼
$0.15
$2K2.431,429 shs6 shs
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
$0.36
-22.2%		$0.83
$0.31
▼
$5.30
$1.64M1.4716.30 million shs6.59 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
0.00%+13.64%+0.81%-41.83%-74.28%
iSpecimen Inc. stock logo
ISPC
iSpecimen
0.00%+17.46%-11.20%-56.04%-95.66%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%0.00%-89.00%+10.00%-95.00%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
0.00%+35.81%-46.76%-66.09%-73.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
$0.11
+3.5%		$0.13
$0.10
▼
$0.60
N/AN/A13,072 shs1,124 shs
iSpecimen Inc. stock logo
ISPC
iSpecimen
$2.24
+0.9%		$2.46
$1.77
▼
$127.20
$3.38M1.66107,006 shs67,517 shs
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.00
$0.01
$0.00
▼
$0.15
$2K2.431,429 shs6 shs
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
$0.36
-22.2%		$0.83
$0.31
▼
$5.30
$1.64M1.4716.30 million shs6.59 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
0.00%+13.64%+0.81%-41.83%-74.28%
iSpecimen Inc. stock logo
ISPC
iSpecimen
0.00%+17.46%-11.20%-56.04%-95.66%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%0.00%-89.00%+10.00%-95.00%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
0.00%+35.81%-46.76%-66.09%-73.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
0.00
N/AN/AN/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
1.00
SellN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00
N/AN/AN/A
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest VIVS, ISPC, TBIO, and BFRGW Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
iSpecimen Inc. stock logo
ISPC
iSpecimen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
5/22/2026
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
$116.67KN/AN/AN/AN/AN/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
$1.93M1.76N/AN/A$14.57 per share0.15
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$225.09M0.00N/AN/A$0.14 per share0.01
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
$130K9.78N/AN/A($0.42) per share-0.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
N/AN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)
iSpecimen Inc. stock logo
ISPC
iSpecimen
-$10.49M-$72.26N/AN/AN/A-1,080.16%-584.65%-142.48%8/10/2026 (Estimated)
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
-$47.72M-$20.52N/AN/AN/A-336.59%N/A-61.89%8/10/2026 (Estimated)
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
-$13.84M-$5.36N/AN/AN/A-10,567.17%-277.62%-153.77%N/A

Latest VIVS, ISPC, TBIO, and BFRGW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026N/A
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
-$0.11N/AN/AN/AN/AN/A
8/10/2026N/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
-$6.39N/AN/AN/A$2.53 millionN/A
7/14/2026Q4 2026
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/A-$2.21N/A-$2.21N/A$0.04 million
5/15/2026Q1 2026
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/A-$6.66N/A-$6.66N/A$0.16 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
N/AN/AN/AN/AN/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/A
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
N/AN/AN/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/A
0.62
0.62
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/A
1.23
1.06
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/A
2.38
2.38

Institutional Ownership

CompanyInstitutional Ownership
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
N/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
13.62%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
37.63%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
8.23%

Insider Ownership

CompanyInsider Ownership
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
N/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
12.20%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
24.50%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
2N/AN/ANot Optionable
iSpecimen Inc. stock logo
ISPC
iSpecimen
601.52 million1.34 millionNot Optionable
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
2001.80 million1.36 millionNo Data
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
203.49 million3.41 millionN/A

Recent News About These Companies

VivoSim Provides Financial and Listing Compliance Update
August 6, 2026  |  financialpost.comF
VivoSim Provides Financial and Listing Compliance Update
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340246/37000/en/vivosim-provides-financial-and-listing-compliance-update.html
Response Genetics (OTCMKTS:RGDXQ) versus VivoSim Labs (NASDAQ:VIVS) Financial Review
August 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30938642
VivoSim Labs Sets 2026 Annual Shareholder Meeting Date
July 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vivosim-labs-sets-2026-annual-shareholder-meeting-date?utm_source=marketbeat.com&utm_medium=referral
VivoSim Labs, Inc. (VIVS)
July 28, 2026  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/VIVS/press-releases/
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026  |  financialpost.comF
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330426/37000/en/vivosim-enters-china-with-first-commercial-sales-of-namkind-toxicology-screening-and-efficacy-testing-services.html
VivoSim Labs Earnings Estimates, EPS & Revenue | NASDAQ:VIVS
July 16, 2026  |  benzinga.comhttps://www.benzinga.com/quote/VIVS/earnings
Why Vivosim Labs Shares Are Rocketing on Wednesday?
July 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/news/why-vivosim-labs-shares-are-rocketing-on-wednesday/ar-AA27YpW0
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
July 16, 2026  |  financialpost.comF
VivoSim Labs Announces $4.0 Million Private Placement with Institutional Investor and Warrant Amendment
July 16, 2026  |  quiverquant.comQ
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328441/37000/en/vivosim-announces-pricing-of-4-0-million-private-placement-priced-at-the-market-under-nasdaq-rules-with-a-single-healthcare-focused-institutional-investor.html
Three Biotechs Deliver Catalysts to Watch
July 15, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/three-biotechs-deliver-catalysts-to-watch-1036328350
VivoSim Labs Announces $5 Million Lilly Milestone Payment and FY2027 Revenue Growth Guidance
July 15, 2026  |  quiverquant.comQ
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327689/37000/en/vivosim-receives-5m-milestone-payment-from-eli-lilly-provides-guidance-that-it-expects-revenue-growth-of-500-in-fy2027.html
VivoSim: Fiscal Q4 Earnings Snapshot
July 14, 2026  |  stamfordadvocate.comS
VivoSim Labs Delays Annual SEC Filing
June 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vivosim-labs-delays-annual-sec-filing?utm_source=marketbeat.com&utm_medium=referral
VivoSim Skids on Data
June 29, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23570/VivoSim-Skids-on-Data
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
June 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/29/3318919/37000/en/vivosim-presents-data-showing-superiority-to-competition-in-nam-liver-tox-prediction-at-european-toxicology-meeting.html
VivoSim Labs, Inc. Common Stock (VIVS) SEC Filings
June 29, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/vivs/sec-filings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bullfrog AI stock logo

Bullfrog AI NASDAQ:BFRGW

$0.11 +0.00 (+3.54%)
As of 12:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

iSpecimen stock logo

iSpecimen NASDAQ:ISPC

$2.24 +0.02 (+0.90%)
As of 04:00 PM Eastern

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Telesis Bio stock logo

Telesis Bio NASDAQ:TBIO

$0.0011 0.00 (0.00%)
As of 08/7/2026

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

VivoSim Labs stock logo

VivoSim Labs NASDAQ:VIVS

$0.36 -0.10 (-22.16%)
As of 04:00 PM Eastern

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas